Toggle navigation
Home
Search
Services
Blog
Contact
About
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter
Idec Pharmaceuticals Corporation, San Diego, CA, United States
Search 10 grants from Peter Brams
Search grants from Idec Pharmaceuticals Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Machine learning to inform health services and policy for traumatic brain injury
Functional data analytics for kinematic assessments of motor control
Non-genomic actions of estrogen in breast cancer
Spatial language in normal and aphasic subjects
Annamycin - Mechanisms of Action
Recently added grants:
Mexican American Drinking Contexts On and Away from the U.S./Mexico Border
Social Ecological Contexts of Heavy Drinking and Alcohol Use Disorders
Role of SAP30 in hypoxia inducible factor activation and breast cancer progression
Framework for Behavioral Risk Models of Alcohol Problems
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AI036027-02A1
Application #
2072058
Study Section
Special Emphasis Panel (ZRG7-SSS-4 (02))
Project Start
1994-08-15
Project End
1998-04-30
Budget Start
1996-05-01
Budget End
1997-04-30
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Idec Pharmaceuticals Corporation
Department
Type
DUNS #
City
San Diego
State
CA
Country
United States
Zip Code
92121
Related projects
NIH 1997
R44 AI
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter / Idec Pharmaceuticals Corporation
NIH 1996
R44 AI
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter / Idec Pharmaceuticals Corporation
Comments
Be the first to comment on Peter Brams's grant